Cumberland Pharmaceuticals (CPIX) Expected to Announce Earnings on Tuesday

Key Points

• Cumberland Pharmaceuticals will report Q1 2026 results after the close on Tuesday, May 5, 2026 at 4:30 PM ET; analysts expect EPS of ($0.13) and revenue of $8.503 million.
• The stock opened at $4.19 with a market cap of $62.7 million, a negative P/E (−22.05) and a 12‑month range of $1.85–$6.26, highlighting small‑cap volatility.
• Institutional ownership is about 15.51% with several funds adding positions recently, while analyst sentiment is mixed — MarketBeat shows a consensus Sell despite at least one upgrade to Buy.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) is projected to post its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect Cumberland Pharmaceuticals to post earnings of ($0.13) per share and revenue of $8.5030 million for the quarter. Individuals can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Cumberland Pharmaceuticals Stock Performance

NASDAQ:CPIX opened at $4.19 on Tuesday. The company's 50-day moving average price is $3.43 and its 200-day moving average price is $3.40. The company has a current ratio of 1.01, a quick ratio of 0.84 and a debt-to-equity ratio of 0.21. The company has a market cap of $62.67 million, a P/E ratio of -22.05 and a beta of -0.33. Cumberland Pharmaceuticals has a twelve month low of $1.85 and a twelve month high of $6.26.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in Cumberland Pharmaceuticals during the second quarter worth about $34,000. Two Sigma Investments LP increased its position in Cumberland Pharmaceuticals by 16.5% during the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company's stock worth $117,000 after purchasing an additional 5,326 shares during the last quarter. Marshall Wace LLP acquired a new stake in Cumberland Pharmaceuticals during the fourth quarter worth about $192,000. Geode Capital Management LLC increased its position in Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company's stock worth $427,000 after purchasing an additional 5,653 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in Cumberland Pharmaceuticals by 2.3% during the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company's stock worth $631,000 after purchasing an additional 4,200 shares during the last quarter. 15.51% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Cumberland Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, March 14th. Weiss Ratings restated a "sell (d-)" rating on shares of Cumberland Pharmaceuticals in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of "Sell".

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc NASDAQ: CPIX is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland's strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company's flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.